Skip to Content

Jing Yang

Present Title & Affiliation

Primary Appointment

Assistant Professor, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Regular Member, Graduate Faculty, The Graduate School of Biomedical Sciences (GSBS), The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2002 Xiangya Medical School, Central South University, Changsha, China, PHD, Molecular Biology
1994 Guangzhou Medical College, Guangzhou, China, MS, Tumor Biology
1991 Guangzhou Normal College, Guangzhou, China, BS, Biology

Postgraduate Training

2004-2008 Research Fellowship, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
2004 Research Fellowship, Myeloma Institute of Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR

Honors and Awards

2009-present K99/R00, National Cancer Institute
2008-2010 ASH Scholar Award, American Society of Hematology
2008 Brian D. Novis Research Award, International Myeloma Foundation
2007 ASH Travel Award, 49th American Society of Hematology
2006 Altana Pharma Publication Award, MD Anderson Cancer Center
2003-2004 National Nature Science Foundation of China, National Nature Science Foundation of China
2001 Scholarship of Central South University in China, Central South University in China
2001 Tan Jiazhen-Fudan University Life Science Award in China, Tan Jiazhen-Fudan University

Selected Publications

Peer-Reviewed Original Research Articles

1. Zhang M, He J, Liu Z, Lu Y, Zheng Y, Li H, Xu J, Liu H, Qian J, Orlowski RZ, Kwak LW, Yi Q, Yang J. Anti-β2-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy. Oncotarget 6(11):8567-78, 4/20/2015. e-Pub 3/2015. PMID: 25895124.
2. Hong B, Li H, Zhang M, Xu J, Lu Y, Zheng Y, Qian J, Chang JT, Yang J, Yi Q. p38 MAPK inhibits breast cancer metastasis through regulation of stromal expansion. Int J Cancer 136(1):34-43, 1/1/2015. e-Pub 5/16/2014. PMCID: PMC4200482.
3. He Z, He J, Liu Z, Xu J, Yi SF, Liu H, Yang J. MAPK11 in breast cancer cells enhances osteoclastogenesis and bone resorption. Biochimie 106:24-32, 11/2014. e-Pub 7/2014. PMCID: PMC4250302.
4. Liu Z, Xu J, He J, Zheng Y, Li H, Lu Y, Qian J, Lin P, Weber DM, Yang J, Yi Q. A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance. Blood 124(13):2061-71, 9/2014. e-Pub 7/2014. PMCID: PMC4186536.
5. Zhang M, Qian J, Lan Y, Lu Y, Li H, Hong B, Zheng Y, He J, Yang J, Yi Q. Anti-β2 M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity. Int J Cancer 135(5):1132-41, 9/2014. e-Pub 2/2014. PMID: 24474467.
6. Park J, Li H, Zhang M, Lu Y, Hong B, Zheng Y, He J, Yang J, Qian J, Yi Q. Murine Th9 cells promote the survival of myeloid dendritic cells in cancer immunotherapy. Cancer Immunol Immunother 63(8):835-45, 8/2014. e-Pub 5/2014. PMID: 24841535.
7. Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H, Yang J, Shah JJ, Thomas SK, Wang M, Weber DM, Orlowski RZ. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia 28(2):373-83, 2/2014. e-Pub 6/2013. PMCID: PMC3874423.
8. Gu D, Wang S, Kuiatse I, Wang H, He J, Dai Y, Jones RJ, Bjorklund CC, Yang J, Grant S, Orlowski RZ. Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737. PLoS One 9(9):e103015, 2014. e-Pub 9/2014. PMCID: PMC4151993.
9. Lu Y, Zhang M, Wang S, Hong B, Wang Z, Li H, Zheng Y, Yang J, Davis RE, Qian J, Hou J, Yi Q. p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression. Nat Commun 5:4229, 2014. e-Pub 6/2014. PMCID: PMC4249595.
10. Liu Z, Xu J, Li H, Zheng Y, He J, Liu H, Zhong Y, Lu Y, Hong B, Zhang M, Lin P, Du J, Hou J, Qian J, Kwak LW, Yi Q, Yang J. Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression. PLoS One 8(12):e82453, 12/2013. e-Pub 12/2013. PMCID: PMC3858321.
11. Wang L, Qian J, Lu Y, Li H, Bao H, He D, Liu Z, Zheng Y, He J, Li Y, Neelapu S, Yang J, Kwak LW, Yi Q, Cai Z. Immune evasion evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells. Haematologica 98(9):1458-66, 9/2013. e-Pub 3/2013. PMCID: PMC3762104.
12. Zheng Y, Yang J, Qian J, Qiu P, Hanabuchi S, Lu Y, Wang Z, Liu Z, Li H, He J, Lin P, Weber D, Davis RE, Kwak L, Cai Z, Yi Q. PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia 27(3):702-10, 3/2013. e-Pub 9/2012. PMCID: PMC3652581.
13. Wang L, Zhao Y, Qian J, Sun L, Lu Y, Li H, Li Y, Yang J, Cai Z, Yi Q. Toll-like receptor-4 signaling in mantle cell lymphoma : Effects on tumor growth and immune evasion. Cancer 119(4):782-91, 2/2013. e-Pub 8/2012. PMID: 22915070.
14. He J, Liu Z, Zheng Y, Qian J, Li H, Lu Y, Xu J, Hong B, Zhang M, Lin P, Cai Z, Orlowski RZ, Kwak LW, Yi Q, Yang J. p38 MAPK in Myeloma Cells Regulates Osteoclast and Osteoblast Activity and Induces Bone Destruction. Cancer Res 72(24):6393-402, 12/2012. e-Pub 10/2012. PMCID: PMC3525770.
15. Hong S, Li H, Qian J, Yang J, Lu Y, Yi Q. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity. Clin Exp Immunol 170(2):167-77, 11/2012. PMCID: PMC3482363.
16. Zhang L, Yang J, Qian J, Li H, Romaguera JE, Kwak LW, Wang M, Yi Q. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood 120(18):3783-92, 11/2012. e-Pub 9/2012. PMCID: PMC3488890.
17. Lu Y, Hong S, Li H, Park J, Hong B, Wang L, Zheng Y, Liu Z, Xu J, He J, Yang J, Qian J, Yi Q. The helper 9 cells promote antitumor immune responses in vivo. J Clin Invest 122(11):4160-71, 11/2012. e-Pub 10/2012. PMCID: PMC3484462.
18. Yang J, He J, Wang J, Cao Y, Ling J, Qian J, Lu Y, Li H, Zheng Y, Lan Y, Hong S, Matthews J, Starbuck MW, Navone NM, Orlowski RZ, Lin P, Kwak LW, Yi Q. Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma. Leukemia 26(9):2114-23, 9/2012. e-Pub 3/2012. PMCID: PMC3381862.
19. Zheng Y, Yang J, Qian J, Zhang L, Lu Y, Li H, Lin H, Lan Y, Liu Z, He J, Hong S, Thomas S, Shah J, Baladandayuthapani V, Kwak LW, Yi Q. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. J Mol Med (Berl) 90(6):695-706, 6/2012. e-Pub 12/2011. PMID: 22207485.
20. Hong S, Qian J, Li H, Yang J, Lu Y, Zheng Y, Yi Q. CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma. Cancer Immunol Immunother 61(4):561-71, 4/2012. e-Pub 10/2011. PMID: 22002243.
21. Sun L, Zhang L, Qian J, Yang J, Yi Q, Dong W, Wang M. Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo. Leuk Res 36(3):363-8, 3/2012. e-Pub 10/2011. PMID: 22000823.
22. Qian J, Zheng Y, Zheng C, Wang L, Qin H, Hong S, Li H, Lu Y, He J, Yang J, Neelapu S, Kwak LW, Hou J, Yi Q. Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma. Blood 119(1):161-9, 1/2012. e-Pub 11/2011. PMCID: PMC3251227.
23. Cao Y, Lan Y, Qian J, Zheng Y, Hong S, Li H, Wang M, Kwak LW, Lin D, Yang J, Yi Q. Targeting cell surface β2 -microglobulin by pentameric IgM antibodies. Br J Haematol 154(1):111-21, 7/2011. e-Pub 5/2011. PMCID: PMC3111817.
24. Li H, Hong S, Qian J, Zheng Y, Yang J, Yi Q. Crosstalk between the Bone and Immune systems: Osteoclasts Function as Antigen-Presenting Cells and Activate CD4+ and CD8+ T cells. Blood 116(2):210-7, 7/2010. e-Pub 3/2010. PMCID: PMC2910608.
25. Yang J and Yi Q. Killing tumor cells through their surface beta(2)-microglobulin or major histocompatibility complex class I molecules. Cancer 116(7):1638-45, 4/2010. PMCID: PMC2847067.
26. Zheng Y, Cai Z, Wang S, Zhang X, Qian J, Hong S, Li H, Wang M, Yang J, Yi Q. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 114(17):3625-8, 10/2009. e-Pub 8/2009. PMCID: PMC2766678.
27. Qian J, Hong S, Wang S, Zhang L, Sun L, Wang M, Yang J, Kwak LW, Hou J, Yi Q. Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma. Blood 114(18):3880-9, 8/2009. e-Pub 8/2009. PMID: 19654406.
28. Yang J, Cao Y, Hong S, Li H, QianJ, Kwak LW, and Yi Q. Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma. Clin Cancer Res 15(3):951-9, 2/2009. PMCID: PMC2659684.
29. Wang M, Zhang L, Han XH, Yang J, Qian J, Hong S, Lin P, Shi Y, Romaguera J, Kwak LW and Yi Q. A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma. Clin Cancer Res 14(7):2154-60, 4/2008. PMID: 18381957.
30. Yang J, Zhang X, Wang J, Qian J, Zhang L, Wang M, Kwak LW, Yi Q. Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. Blood 110(8):3028-35, 10/2007. e-Pub 7/2007. PMCID: PMC2018676.
31. Yang J, Wezeman M, Zhang X, Lin P, Wang M, Qian J, Wan B, Kwak LW, Yu L, Yi Q. Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell 12(3):252-65, 9/2007. PMID: 17785206.
32. Yang J, Qian J, Wezeman M, Wang S, Lin P, Wang M, Yaccoby S, Kwak LW, Barlogie B, Yi Q. Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell 10(4):295-307, 10/2006. PMID: 17045207.

Invited Articles

1. Liu H, He J, Yang J. Tumor cell p38 MAPK: A trigger of cancer bone osteolysis. Cancer Cell Microenviron 2(1), 1/2015. PMCID: PMC4448135.

Book Chapters

1. Lu Y, Yang J and Yi Q. Signaling of Tumor-Induced Immunosuppression of Dendritic Cells. In: The Tumor Immunoenviroment. Ed(s) Shuin MR, Umansky V, Mayguine A. Springer: Netherlands, 2013.
2. Yang J and Yi Q. Signaling pathways mediating dendritic cells dysfunction in cancer. In: Dendritic Cells in Cancer. Ed(s) Shurin M and Salter R. Springer, 2009. ISBN: 978-0-387-88610-7.

Grant & Contract Support

Title: A Novel Therapeutic Target for Myeloma Bone Destruction
Funding Source: American Cancer Society (ACS)
Role: Principal Investigator
Duration: 7/1/2015 - 6/30/2019
Title: The role of tumor cell p38 MAPK activity in osteolytic bone lesions in myeloma
Funding Source: American Society of Hematology (ASH)
Role: Principal Investigator
Duration: 7/1/2012 - 6/30/2015
Title: MD Anderson Cancer Center SPORE in Multiple Myeloma Animal Core Facility
Funding Source: NIH/NCI
Role: Core Facility Director
Duration: 7/1/2012 - 6/30/2015
Title: Anti-beta2 microglobulin mAbs as a novel therapeutic agent in multiple myeloma
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/1/2009 - 8/31/2014

Last updated: 7/17/2015